Literature DB >> 10069801

Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail.

A Bishayee1, L Beguinot, S Bishayee.   

Abstract

We reported previously that a conformation-specific antibody, Ab P2, to a 16-amino acid peptide (Glu-Gly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the beta-type platelet-derived growth factor receptor also recognizes the epidermal growth factor (EGF) receptor. Although the antibody is not directed to phosphotyrosine, it recognizes in immunoprecipitation the activated and hence phosphorylated form of both receptors. In P2 peptide, there are two tripeptide sequences, Asp-Glu-Glu and Tyr-Gln-Gln, that are also present in the EGF receptor. Our present studies using either EGF receptor C-terminal deletion mutants or point mutations (Tyr-->Phe) and our previous studies on antibody inhibition by P2-derived peptides suggest that Gln-Gln in combination with Asp-Glu-Glu forms a high-affinity complex with Ab P2 and that such complex formation is dependent on tyrosine phosphorylation. Of the five phosphate acceptor sites in the EGF receptor, clustered in the extreme C-terminal tail, phosphorylation of three tyrosine residues (992, 1068, and 1086) located between Asp-Glu-Glu and Gln-Gln is necessary for Ab P2 binding. In contrast, the acceptor sites Tyr 1173 and 1148 play no role in the conformation change. Asp-Glu-Glu and Gln-Gln are located 169 amino acids apart, and it is highly likely that the interactions among three negatively charged phosphotyrosine residues in the receptor C terminus may result in the bending of the peptide chain in such a way that these two peptides come close to each other to form an antibody-binding site. Such a possibility is also supported by our finding that receptor dephosphorylation results in complete loss of Ab P2-binding activity. In conclusion, we have identified a domain within the cytoplasmic part of the EGF receptor whose conformation is altered by receptor phosphorylation; furthermore, we have identified the tyrosine residues that positively regulate this conformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069801      PMCID: PMC25185          DOI: 10.1091/mbc.10.3.525

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  31 in total

1.  Autophosphorylation of the insulin receptor in vitro. Designation of phosphorylation sites and correlation with receptor kinase activation.

Authors:  R Herrera; O M Rosen
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

2.  Monoclonal antibodies detect conformational abnormality of uracil DNA glycosylase in Bloom's syndrome cells.

Authors:  T M Vollberg; G Seal; M A Sirover
Journal:  Carcinogenesis       Date:  1987-11       Impact factor: 4.944

3.  Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates.

Authors:  G M Walton; W S Chen; M G Rosenfeld; G N Gill
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

4.  Purified human platelet-derived growth factor receptor has ligand-stimulated tyrosine kinase activity.

Authors:  S Bishayee; A H Ross; R Womer; C D Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Receptor modulating properties of an antibody directed against the epidermal growth factor receptor.

Authors:  M Das; B Knowles; R Biswas; S Bishayee
Journal:  Eur J Biochem       Date:  1984-06-01

6.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

7.  Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.

Authors:  S Cohen; G Carpenter; L King
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

8.  Intrapeptide autophosphorylation of the epidermal growth factor receptor: regulation of kinase catalytic function by receptor dimerization.

Authors:  R Biswas; M Basu; A Sen-Majumdar; M Das
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

9.  Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide.

Authors:  U Murthy; A Basu; U Rodeck; M Herlyn; A H Ross; M Das
Journal:  Arch Biochem Biophys       Date:  1987-02-01       Impact factor: 4.013

10.  Perinuclear location and recycling of epidermal growth factor receptor kinase: immunofluorescent visualization using antibodies directed to kinase and extracellular domains.

Authors:  U Murthy; M Basu; A Sen-Majumdar; M Das
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

View more
  13 in total

1.  Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes.

Authors:  Tatiana Gianni; Gabriella Campadelli-Fiume; Laura Menotti
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.

Authors:  Guolin Zhang; Bin Fang; Richard Z Liu; Huiyi Lin; Fumi Kinose; Yun Bai; Umut Oguz; Elizabeth R Remily-Wood; Jiannong Li; Soner Altiok; Steven Eschrich; John Koomen; Eric B Haura
Journal:  J Proteome Res       Date:  2010-12-03       Impact factor: 4.466

3.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

4.  Multiple-state reactions between the epidermal growth factor receptor and Grb2 as observed by using single-molecule analysis.

Authors:  Miki Morimatsu; Hiroaki Takagi; Kosuke G Ota; Ryo Iwamoto; Toshio Yanagida; Yasushi Sako
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

5.  Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Authors:  Angela J Mantha; Kathryn E McFee; Nima Niknejad; Glenwood Goss; Ian A Lorimer; Jim Dimitroulakos
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-26       Impact factor: 4.553

6.  Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Authors:  Jeonghee Cho; Liang Chen; Naveen Sangji; Takafumi Okabe; Kimio Yonesaka; Joshua M Francis; Richard J Flavin; William Johnson; Jihyun Kwon; Soyoung Yu; Heidi Greulich; Bruce E Johnson; Michael J Eck; Pasi A Jänne; Kwok-Kin Wong; Matthew Meyerson
Journal:  Cancer Res       Date:  2013-09-24       Impact factor: 12.701

7.  Molecular biology of gynecological cancer.

Authors:  Kenzo Sonoda
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

8.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

9.  A comprehensive pathway map of epidermal growth factor receptor signaling.

Authors:  Kanae Oda; Yukiko Matsuoka; Akira Funahashi; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

10.  Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.

Authors:  Simona Camorani; Elvira Crescenzi; David Colecchia; Andrea Carpentieri; Angela Amoresano; Monica Fedele; Mario Chiariello; Laura Cerchia
Journal:  Oncotarget       Date:  2015-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.